AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
AEON Biopharma, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 49.88M shares outstanding
USAEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Leadership
Alex Wilson
Chief Legal & Strategy Officer and Corporate Secretary
Chad Oh, M.D.
Chief Medical Officer
Jennifer Sy
Chief Accounting Officer
John Bencich
Chief Financial Officer
Employees
8
Country
US
Sector
Healthcare
Website
aeonbiopharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 LYNCH TIMOTHY P | 10% Owner | Purchase | 1.15M | $243.5K | Aug 19, 2026 |
 Carter Eric G | Director | Grant/Award | 222.7K | -- | Jun 17, 2026 |
 Thunen Shelley B | Director | Grant/Award | 222.7K | -- | Jun 17, 2026 |
 PALMISANO ROBERT J | Director | Grant/Award | 222.7K | -- | Jun 17, 2026 |
 Forth Marc | Director | Grant/Award | 222.7K | -- | Jun 17, 2026 |
 FISCHER JOST | Director | Grant/Award | 222.7K | -- | Jun 17, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Dauntless Investment Group, LLC | 12.5M | 25.0% | 13F |
Daewoong Co.,Ltd. (\"DWC\") · may incl. warrants· filed Jan 2026 | 12.0M | 24.1% | 13D |
Timothy P. Lynch · may incl. warrants· filed Sep 2026 | 6.5M | 13.0% | 13G |
 Bancroft Robert E. PRESIDENT & CEO, Director | 3.2M | 6.4% | FORM 4 |
 Oh Chad CHIEF MEDICAL OFFICER | 2.2M | 4.4% | FORM 4 |
 Wilson Alexander Blair CLO, CSO, and Corp Secretary | 2.2M | 4.4% | FORM 4 |
 Sy Jennifer PRINCIPAL ACCOUNTING OFFICER | 1.5M | 3.0% | FORM 4 |
Chernett Jorey · may incl. warrants· filed May 2025 | 1.1M | 2.3% | 13G |
 Forth Marc Director | 973.2K | 2.0% | FORM 4 |
 Bencich John CHIEF FINANCIAL OFFICER | 754.7K | 1.5% | FORM 4 |
Insiders
- LYNCH TIMOTHY P10% Owner
- Carter Eric GDirector
- Thunen Shelley BDirector
- PALMISANO ROBERT JDirector
- Forth MarcDirector
- FISCHER JOSTDirector
- Bencich JohnCHIEF FINANCIAL OFFICER
- Oh ChadCHIEF MEDICAL OFFICER
- Wilson Alexander BlairCLO, CSO, and Corp Secretary
- Sy JenniferPRINCIPAL ACCOUNTING OFFICER
based on 49.88M shares outstanding
US30d Avg
6.45M
60d Avg
9.66M
90d Avg
7.74M